{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:37:06Z","timestamp":1794530226934,"version":"4.9.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["705056"],"award-info":[{"award-number":["705056"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["409302"],"award-info":[{"award-number":["409302"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["JO 1598\/1-1"],"award-info":[{"award-number":["JO 1598\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 3060\/8-1"],"award-info":[{"award-number":["HA 3060\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Federation Enfants et Sant\u00e9","id":[{"id":"https:\/\/ror.org\/008hqmq07","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical teratoid\/rhabdoid tumors (ATRTs) are known to exhibit molecular and clinical heterogeneity even though SMARCB1 inactivation is the sole recurrent genetic event present in nearly all cases. Indeed, recent studies demonstrated 3 molecular subgroups of ATRTs that are genetically, epigenetically, and clinically distinct. As these studies included different numbers of tumors, various subgrouping techniques, and naming, an international working group sought to align previous findings and to reach a consensus on nomenclature and clinicopathological significance of ATRT subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated various methods to perform a meta-analysis on published and unpublished DNA methylation and gene expression datasets of ATRTs and associated clinicopathological data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In concordance with previous studies, the analyses identified 3 main molecular subgroups of ATRTs, for which a consensus was reached to name them ATRT-TYR, ATRT-SHH, and ATRT-MYC. The ATRT-SHH subgroup exhibited further heterogeneity, segregating further into 2 subtypes associated with a predominant supratentorial (ATRT-SHH-1) or infratentorial (ATRT-SHH-2) location. For each ATRT subgroup we provide an overview of its main molecular and clinical characteristics, including SMARCB1 alterations and pathway activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The introduction of a common classification, characterization, and nomenclature of ATRT subgroups will facilitate future research and serve as a common ground for subgrouping patient samples and ATRT models, which will aid in refining subgroup-based therapies for ATRT patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noz235","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T15:17:09Z","timestamp":1576595829000},"page":"613-624","source":"Crossref","is-referenced-by-count":233,"title":["Molecular subgrouping of atypical teratoid\/rhabdoid tumors\u2014a reinvestigation and current consensus"],"prefix":"10.1093","volume":"22","author":[{"given":"Ben","family":"Ho","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal D","family":"Johann","sequence":"additional","affiliation":[{"name":"Hopp Children\u2019s Cancer Center, Heidelberg, Germany"},{"name":"Division of Pediatric Neuro-oncology, German Cancer Research Center and German Cancer Research Consortium, Heidelberg, Germany"},{"name":"Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yura","family":"Grabovska","sequence":"additional","affiliation":[{"name":"Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamy Jean","family":"De Dieu Andrianteranagna","sequence":"additional","affiliation":[{"name":"Departments of Genetics and of Oncopediatry and Young Adults, Curie Institute, Paris, France"},{"name":"INSERM U830, Laboratory of Translational Research in Pediatric Oncology, SIREDO Pediatric Oncology Center, Curie Institute, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fupan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fr\u00fchwald","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital Augsburg, Swabian Children\u2019s Cancer Center, Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hasselblatt","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bourdeaut","sequence":"additional","affiliation":[{"name":"Departments of Genetics and of Oncopediatry and Young Adults, Curie Institute, Paris, France"},{"name":"INSERM U830, Laboratory of Translational Research in Pediatric Oncology, SIREDO Pediatric Oncology Center, Curie Institute, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Williamson","sequence":"additional","affiliation":[{"name":"Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kool","sequence":"additional","affiliation":[{"name":"Hopp Children\u2019s Cancer Center, Heidelberg, Germany"},{"name":"Division of Pediatric Neuro-oncology, German Cancer Research Center and German Cancer Research Consortium, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,31]]},"reference":[{"issue":"6","key":"2020120707032127900_CIT0001","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/neuonc\/nov264","article-title":"Atypical teratoid\/rhabdoid tumors\u2014current concepts, advances in biology, and potential future therapies","volume":"18","author":"Fr\u00fchwald","year":"2016","journal-title":"Neuro Oncol."},{"issue":"3","key":"2020120707032127900_CIT0002","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00401-014-1323-x","article-title":"SMARCA4-mutated atypical teratoid\/rhabdoid tumors are associated with inherited germline alterations and poor prognosis","volume":"128","author":"Hasselblatt","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2020120707032127900_CIT0003","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajhg.2010.01.013","article-title":"Germline nonsense mutation and somatic inactivation of SMARCA4\/BRG1 in a family with rhabdoid tumor predisposition syndrome","volume":"86","author":"Schneppenheim","year":"2010","journal-title":"Am J Hum Genet."},{"key":"2020120707032127900_CIT0004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fonc.2012.00114","article-title":"Atypical teratoid rhabdoid tumor: current therapy and future directions","volume":"2","author":"Ginn","year":"2012","journal-title":"Front Oncol."},{"issue":"12","key":"2020120707032127900_CIT0005","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/neuonc\/nor140","article-title":"High expression of BMP pathway genes distinguishes a subset of atypical teratoid\/rhabdoid tumors associated with shorter survival","volume":"13","author":"Birks","year":"2011","journal-title":"Neuro Oncol."},{"issue":"5","key":"2020120707032127900_CIT0006","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(15)70114-2","article-title":"Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis","volume":"16","author":"Torchia","year":"2015","journal-title":"Lancet Oncol."},{"issue":"6","key":"2020120707032127900_CIT0007","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ccell.2016.11.003","article-title":"Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors","volume":"30","author":"Torchia","year":"2016","journal-title":"Cancer Cell."},{"issue":"3","key":"2020120707032127900_CIT0008","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccell.2016.02.001","article-title":"Atypical teratoid\/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes","volume":"29","author":"Johann","year":"2016","journal-title":"Cancer Cell."},{"issue":"7697","key":"2020120707032127900_CIT0009","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature."},{"issue":"7","key":"2020120707032127900_CIT0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1470-2045(17)30243-7","article-title":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study","volume":"18","author":"Schwalbe","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"2020120707032127900_CIT0011","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","article-title":"Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes","volume":"138","author":"Sharma","year":"2019","journal-title":"Acta Neuropathol."},{"key":"2020120707032127900_CIT0012","doi-asserted-by":"crossref","first-page":"10421","DOI":"10.1038\/ncomms10421","article-title":"The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation","volume":"7","author":"Han","year":"2016","journal-title":"Nat Commun."},{"issue":"21","key":"2020120707032127900_CIT0013","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-15-0874","article-title":"Generation of a mouse model of atypical teratoid\/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53","volume":"75","author":"Ng","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"2020120707032127900_CIT0014","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41467-017-00346-5","article-title":"Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development","volume":"8","author":"Vitte","year":"2017","journal-title":"Nat Commun."},{"key":"2020120707032127900_CIT0015","article-title":"Tyrosinase immunohistochemistry can be employed for the diagnosis of atypical teratoid\/rhabdoid tumours of the tyrosinase subgroup (ATRT-TYR)","author":"Hasselblatt","year":"2019","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"2","key":"2020120707032127900_CIT0016","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1242\/dev.105445","article-title":"Establishing neural crest identity: a gene regulatory recipe","volume":"142","author":"Sim\u00f5es-Costa","year":"2015","journal-title":"Development."},{"issue":"4","key":"2020120707032127900_CIT0017","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I","article-title":"Tyrosinase is a new marker for cell populations in the mouse neural tube","volume":"205","author":"Tief","year":"1996","journal-title":"Dev Dyn."},{"issue":"4","key":"2020120707032127900_CIT0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bpa.12413","article-title":"Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome","volume":"27","author":"Johann","year":"2017","journal-title":"Brain Pathol."},{"issue":"12","key":"2020120707032127900_CIT0019","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/neuonc\/noy111","article-title":"Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid\/rhabdoid tumor","volume":"20","author":"Nowak","year":"2018","journal-title":"Neuro Oncol."},{"issue":"11","key":"2020120707032127900_CIT0020","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-018-0207-3","article-title":"A biobank of patient-derived pediatric brain tumor models","volume":"24","author":"Brabetz","year":"2018","journal-title":"Nat Med."},{"issue":"2","key":"2020120707032127900_CIT0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/NEN.0000000000000161","article-title":"The chromatin-modifying protein HMGA2 promotes atypical teratoid\/rhabdoid cell tumorigenicity","volume":"74","author":"Kaur","year":"2015","journal-title":"J Neuropathol Exp Neurol."},{"issue":"5","key":"2020120707032127900_CIT0022","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.celrep.2016.10.005","article-title":"Dual targeting of PDGFR\u03b1 and FGFR1 displays synergistic efficacy in malignant rhabdoid tumors","volume":"17","author":"Wong","year":"2016","journal-title":"Cell Rep."},{"issue":"7","key":"2020120707032127900_CIT0023","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.celrep.2017.10.076","article-title":"High-throughput drug screening identifies pazopanib and clofilium tosylate as promising treatments for malignant rhabdoid tumors","volume":"21","author":"Chauvin","year":"2017","journal-title":"Cell Rep."},{"issue":"12","key":"2020120707032127900_CIT0024","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2251","article-title":"Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway","volume":"16","author":"Jagani","year":"2010","journal-title":"Nat Med."},{"issue":"4","key":"2020120707032127900_CIT0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ijc.28719","article-title":"Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1","volume":"135","author":"Kerl","year":"2014","journal-title":"Int J Cancer."},{"issue":"4","key":"2020120707032127900_CIT0026","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"2020120707032127900_CIT0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ccell.2018.11.014","article-title":"Comprehensive analysis of chromatin states in atypical teratoid\/rhabdoid tumor identifies diverging roles for SWI\/SNF and polycomb in gene regulation","volume":"35","author":"Erkek","year":"2019","journal-title":"Cancer Cell."},{"issue":"6","key":"2020120707032127900_CIT0028","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/ejh.12396","article-title":"Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature","volume":"94","author":"Alig","year":"2015","journal-title":"Eur J Haematol."},{"issue":"2","key":"2020120707032127900_CIT0029","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00401-018-1814-2","article-title":"Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous","volume":"136","author":"Pinto","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"8","key":"2020120707032127900_CIT0030","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.celrep.2019.10.013","article-title":"Identification and analyses of extra-cranial and cranial rhabdoid tumor molecular subgroups reveal tumors with cytotoxic T cell infiltration","volume":"29","author":"Chun","year":"2019","journal-title":"Cell Rep."},{"issue":"11","key":"2020120707032127900_CIT0031","first-page":"1519","article-title":"Inhibition of DNA damage repair by the CDK4\/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth","volume":"18","author":"Hashizume","year":"2016","journal-title":"Neuro Oncol."},{"issue":"9","key":"2020120707032127900_CIT0032","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/j.celrep.2019.07.021","article-title":"Small-molecule and CRISPR screening converge to reveal receptor tyrosine kinase dependencies in pediatric rhabdoid tumors","volume":"28","author":"Oberlick","year":"2019","journal-title":"Cell Rep."},{"issue":"4","key":"2020120707032127900_CIT0033","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: the current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2020120707032127900_CIT0034","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","article-title":"The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants","volume":"133","author":"Pajtler","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2020120707032127900_CIT0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell."},{"issue":"2","key":"2020120707032127900_CIT0036","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00401-018-1888-x","article-title":"Heterogeneity within the PF-EPN-B ependymoma subgroup","volume":"136","author":"Cavalli","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2020120707032127900_CIT0037","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell."},{"issue":"8","key":"2020120707032127900_CIT0038","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.celrep.2019.10.013","article-title":"Identification and analyses of extra-cranial and cranial rhabdoid tumor molecular subgroups reveal tumors with cytotoxic T cell infiltration","volume":"29","author":"Chun","year":"2019","journal-title":"Cell Rep."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noz235\/32529401\/noz235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/5\/613\/34743940\/noz235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/5\/613\/34743940\/noz235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T08:35:56Z","timestamp":1607330156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/22\/5\/613\/5691191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,31]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,12,31]]},"published-print":{"date-parts":[[2020,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noz235","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,12,31]]}}}